Kymera Therapeutics

Press Releases

Kymera Therapeutics to Present Preclinical Data on its First-in-Class Selective and Potent Oral IRAK4 Degraders in Cutaneous Inflammation

Kymera Therapeutics Inc., a biotechnology company pioneering targeted protein degradation to discover breakthrough medicines for patients, today announced the company will present preclinical data demonstrating that oral daily dosing of its IRAK4 degraders completely suppressed IRAK4 protein expression in skin and immune cells and inhibited cutaneous inflammation.

Kymera Therapeutics to Present Preclinical Data Demonstrating Potent Antitumor Activity by a Selective STAT3 Degrader in Hematologic Malignancies at the American Society of Hematology Annual Meeting

Kymera Therapeutics Inc., a biotechnology company pioneering targeted protein degradation to discover breakthrough medicines for patients, today announced the company will present new preclinical data showing the further characterization of novel, highly selective and potent degraders of STAT3 with activity across multiple hematologic malignancies including ALK-positive anaplastic large cell lymphoma (ALK+ ALCL), acute myelogenous leukemia (AML) and diffuse large B cell lymphoma (DLBCL).

Kymera Therapeutics Promotes Nello Mainolfi, PhD, to Chief Executive Officer

Kymera Therapeutics Inc., a biotechnology company pioneering targeted protein degradation to discover breakthrough therapies for patients, today announced Kymera Co-founder, President and Chief Scientific Officer Nello Mainolfi, PhD, has been promoted to President and Chief Executive Officer effective immediately. Mainolfi will lead Kymera as the company enters its next stage of growth, advancing a series of novel degrader drugs into clinical development as well as expanding the impact of its innovative Pegasus™ platform.

View All Press Releases

Blog

Kymera’s IRAK4 degrader for hidradenitis suppurativa: Hitting an elusive target hard for a hard-to-treat inflammatory disease

IRAK4 is a key component of the myddosome, a protein complex that transmits signals from toll-like receptors (TLRs) and IL-1 receptors (IL-1Rs) to activate the innate immune response to infectious pathogens.

Targeted Protein Degradation Comes of Age (As Featured in LifeSciVC)

Translation of well validated biology into therapeutics remains one of the biggest challenges of modern drug development, in many cases due to lack of appropriate technologies to drug well credentialed biological targets. Examples in this category include driver oncogenes such as MYC, b-catenin and STAT3; catalytically active scaffolding kinases such as IRAK4 and RIPK’s or proteins whose accumulation is associated with well-established pathology such as alpha-synuclein in Parkinsons’s Disease or Tau in dementia and Alzheimer’s Disease.

Going after the “undruggable”: the STAT3 story

Targeted protein degradation (TPD) is one of the most promising and exciting therapeutic modalities today, with the potential to effectively target disease-causing proteins and signaling pathways that have long been out of reach with conventional therapeutic approaches. These are proteins that either lack catalytic activity and/or have catalytic-independent functions – targets that to date have either gone “undrugged” or have not been adequately addressed.

View All Blog Posts